AUS
NZ
UK
CA
USA
IND
Highlights:
- Zoetis shares opened at $167.23 with a market capitalization of $75.45 billion.
- The company has a 52-week low of $144.80 and a 52-week high of $200.53.
- Zoetis maintains a debt-to-equity ratio of 1.26 and a quick ratio of 2.27.
Zoetis (NYSE:ZTS) is a key player in the animal health sector, providing a broad range of products for both livestock and pets. The company's portfolio includes pharmaceuticals and diagnostic products essential for maintaining the health and well-being of animals. With a focus on innovation and quality, Zoetis supports veterinarians and animal care providers globally in their efforts to enhance animal health.
Stock Performance Overview
Zoetis shares opened at $167.23, reflecting a market capitalization of $75.45 billion. The price-to-earnings ratio of 31.43 indicates how the stock price compares to the company’s earnings, while the price-to-earnings-growth ratio of 2.91 provides a further perspective on its valuation relative to expected growth. These figures provide an insight into how the market values Zoetis in the context of its earnings and growth trajectory.
Recent Trading Movements
The fifty-day moving average for Zoetis stands at $171.31, while the two-hundred-day moving average is slightly higher at $180.16. These moving averages show how the stock price has shifted in both the short and longer term. The 52-week range for the stock spans a low of $144.80 and a high of $200.53, highlighting the fluctuations in Zoetis’ stock price over the past year.
Liquidity and Debt Metrics
Zoetis demonstrates solid financial health with a quick ratio of 2.27, indicating the company’s ability to meet short-term obligations without relying on inventory. The current ratio of 3.69 further supports the company’s strong liquidity position, showing ample coverage for short-term liabilities with assets. Additionally, Zoetis’ debt-to-equity ratio is 1.26, reflecting the degree to which the company relies on debt financing in its capital structure.
Zoetis continues to maintain a strong presence in the animal health industry, with financial metrics that reflect stability and consistent performance. Through its diverse product offerings and solid financial ratios, Zoetis remains an integral company in the veterinary pharmaceuticals and diagnostics space.
